Welcome to MS Australia
The Federal Government today announced the listing of Ocrevus ™ (ocrelizumab) for relapsing remitting MS (RRMS) on the Pharmaceutical Benefits Scheme (PBS).
In 2017, Ocrevus ™ was registered for use in Australia by the Therapeutic Goods Administration (TGA), for the treatment of patients with RRMS, to delay the progression of physical disability and to reduce the frequency of relapse. Ocrevus ™ was also registered for use in people...
There are currently no Upcoming Events. Please check again soon!